Viemed Healthcare, Inc.
Viemed Healthcare, Inc., through its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The company provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive…
1D
-2.8%
1W
-0.4%
1M
+6.0%
6M
-2.7%
YTD
+27.6%
1Y
+38.4%
2Y
+4.4%
5Y
+64.3%
10Y
–
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~22% stronger price swings than usual
PRICE TARGET LOW
US$14.00
CONSENSUS
US$14.00
MEDIAN
US$14.00
PRICE TARGET HIGH
US$14.00
0
STRONG BUY
1
BUY
1
HOLD
0
SELL
0
STRONG SELL
2
TOTAL · Buy
As of: 06/08/2026
P/E
25.13
P/B
2.52
EV/EBITDA
6.75
RETURN ON EQUITY
1.9%
NET MARGIN
3.5%
DEBT/EQUITY
0.08
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
FREE FLOAT
86.1%
FLOAT SHARES
32,781,508
AVG. DAILY VOLUME (30D)
260,955
Heltz Sabrina
Dobbs Randy E.
Smokoff Timothy
Smokoff Timothy
Smokoff Timothy
Viemed Healthcare, Inc. is a company in the Healthcare sector, Medical - Care Facilities industry, headquartered in United States.
The CEO is Casey Hoyt, the company employs around 1,438 people.
The IPO was on 09/08/2019; the stock trades on NASDAQ under the ticker VMD.
2 analysts rate the stock, the consensus is Buy (as of 06/08/2026).
The average price target is US$14.00, ranging from US$14.00 to US$14.00, with a median of US$14.00.
This is an external assessment, not a statement by Market Jury.
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 22% stronger than usual.
No, Viemed Healthcare currently does not pay a dividend.
Comparable stocks include HCA Healthcare, Tenet Healthcare, DaVita, Universal Health Services, Hims & Hers Health, LifeStance Health Group, Concentra Group Holdings Parent and Acadia Healthcare Company.
Clicking "Analyze stock" lets five strategies assess Viemed Healthcare against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.